Immunovant, Inc. (IMVT)
↓ Download CSVKey ratios (FY2026)
-59.3%
Return on equity
| Metric (FY) | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$505.61M | -$413.84M | -$259.34M | -$210.96M | -$156.73M | -$107.43M | -$66.39M | -$28.60M | — |
| EPS (Diluted) | $-2.77 | $-2.73 | $-1.88 | $-1.71 | $-1.43 | $-1.22 | — | — | — |
| Total Assets | $957.01M | $776.22M | $666.37M | $405.84M | $515.56M | $412.49M | $109.39M | $13.83M | — |
| Total Liabilities | $104.42M | $68.78M | $48.61M | $43.34M | $45.74M | $21.01M | $15.32M | $6.49M | — |
| Shareholders' Equity | $852.59M | $707.45M | $617.76M | $362.49M | $469.82M | $391.48M | $94.07M | $7.34M | -$411.0K |
| Cash & Equivalents | $902.11M | $713.97M | $635.37M | $376.53M | $493.82M | $400.15M | $100.57M | $6.99M | — |
| Operating Cash Flow | -$407.31M | -$375.87M | -$214.23M | -$188.19M | -$106.11M | -$83.33M | -$53.36M | -$28.55M | — |
| Capital Expenditures | $8.0K | $759.0K | $360.0K | $197.0K | $254.0K | $210.0K | $31.0K | $52.0K | — |
| Shares Outstanding | 203.94M | 170.11M | 145.58M | 130.33M | 116.48M | 97.97M | 54.66M | 38.59M | — |